Latest ALK inhibitor Stories

HILDEN, Germany and GERMANTOWN, Maryland, January 7, 2013 /PRNewswire/ -- - QIAGEN invests in new companion diagnostic being developed by Drug Response Dx that aims to predict efficacy of TNF-alpha inhibitors in rheumatoid arthritis patients - Rights to RET, ROS1 and DEPDC1 biomarkers gained from Insight Genetics offer promise as companion diagnostics in lung cancer - New tests from Inserm for mutations of HSP110 gene...

ABBOTT PARK, Ill., Oct. 24, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will expand the current CE-IVD product labeling for its Vysis(®) ALK Break Apart FISH Probe Kit, allowing the test to be marketed in the European Union as a companion diagnostic. The test is designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in advanced non-small cell lung cancer (NSCLC) patients who may be eligible for treatment with XALKORI (crizotinib), an oral...